Indazolyl-substituted pyrroline compounds as kinase inhibitors

Details Indazolyl-substituted pyrroline compounds as kinase inhibitors Indazolyl-substituted pyrroline compounds as kinase inhibitors

2005-02-01

2005-02-01

McKane, Joseph K. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S314000, C514S339000, C546S139000, C546S152000, C546S275700

Reexamination Certificate

active

06849643

ABSTRACT:
The present invention is directed to novel indazolyl-substituted pyrroline compounds of Formula (I):useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.

REFERENCES:
patent: 5057614 (1991-10-01), Davis et al.
patent: 5624949 (1997-04-01), Heath, Jr. et al.
patent: 5721245 (1998-02-01), Davis et al.
patent: 1057484 (2000-12-01), None
patent: 1120414 (2001-08-01), None
patent: WO 9517182 (1995-06-01), None
patent: WO 9811102 (1998-03-01), None
patent: WO 0006564 (2000-02-01), None
patent: WO 0021927 (2000-04-01), None
Davis, P.D. et al.: “Inhibitors of Protein Kinase C1.2,3-Bisarylmaleimides” Journal of Medicinal Chemistry, American Chemical Society. Washington, D.C., U.S. vol. 35, no.1, 1992, pp. 177-184.
PCT Search Report dated Oct. 8, 2003 for PCT/US03/17569.
P. Xia, et al., “J. Clin. Invest.”, 1996, 98, 2018.
H. Ishii, et al., “J. Mol. Med.”, 1998, 72, 21.
Inoguchi, et al., “Proc. Natl. Acad. Sci. USA”, 1992, 89, 11059-11065.
Bastyr III, E.J. and Lu, J., “Diabetes”, 1993, 42 (Suppl. 1) 97A.
Hsieh, et al., “Proc. Natl. Acad. Sci. USA”, 1991, 88, 9315-9319.
Hsieh, et al., “J. Biol. Chem.” 1993, 268, 15118-15126.
Murray, et al., “J. Biol. Chem.”, 1993, 268, 15847-15853.
Tamaoki, et al., “Biochem. Biophys. Res. Commun.”, 1986, 135, 397-402.
Gross, et al., “Biochem. Pharmacol.”, 1990, 40, 343-350.
Prudhomme, “Curr. Pharm Design”, 1997, 3, 265-290.
Pindur, et al., “Curr. Med. Chem.” 1999, 6, 29-69.
Ruegg, U.T. and Burgess, G.M., “Trends Pharmacol. Sci.” 1989, 10, 218-220.
Davis, et al., “FEBS Lett.”, 1989, 259, 61-63.
Twoemy, et al., “Biochem Biophys. Res., Commun.”, 1990, 171, 1087-1092.
Touilec et al., “J. Biol. Chem” 1991, 266, 15771-15781.
Davis et al., “J. Med. Chem.” 1992, 35, 994-1001.
Bit, et al., “J. Med. Chem.”, 1993, 26, 21-29.
McGlynn, et al., “J. Cell. Biochem.”, 1992, 49, 239-250.
Ward, N.E. and O'Brian, C.A., “Molec. Pharmacol.” 1992, 41, 387-392.
Martiny-Baron, et al., “J. Biol. Chem.”, 1993, 268, 9194-9197.
Wilkinson et al., “Biochem J.”, 1993, 294, 335-337.
Jirousek et al., “J. Med. Chem.”, 1996, 39, 2664-2671.
Hong Hu, “Drug Discovery Today”, 1996, 1, 438-447.
Geokjian et al., “Curr. Med. Chem.” 1999, 6, 877-903.
Mulqueen, M.J., et al., “Agents Actions”, 1992, 37, 85-89.
Huang, K.P., “Trends Neurosci.”, 1989, 12, 425-432.
Hara, H., et al., “J. Cereb. Blood Flow Metab.”, 1990, 10, 646-653.
Shibata, S., et al., “Brain Res.”, 1992, 594, 290-294.
Shimohama, S., et al., “Neurology”, 1993, 43, 1407-1413.
Rotenberg, S.A. and Weinstein, I.B., “Biochem. Mol. Aspects Sel. Cancer”, 1991, 1, 25-73.
Ahmad et al., “Molecular Pharmacology”, 1993, 43, 858-862.
Meyer, T., et al., “Int. J. Cancer”, 1989, 43, 851-856.
Akinagaka, S., et al., “Cancer Res.”, 1991, 51, 4888-4892.
Matsumoto, H. and Sasaki Y., “Biochem. Biophys. Res. Commun.” 1989, 158, 105-109.
X. Gu et al., “Circ. Res”, 199, 75, 926.
H. Wakasaki et al., “Proc. Natl. Acad. Sci. USA”, 1997, 94, 9320.
Bilder, G.E., et al., “J. Pharmacol. Exp. Ther.”, 1990, 252, 526-530.
Muid, R.E., et al., “FEBS Lett.”, 1990, 293, 169-172.
Sonoki, H., et al., “Kokyu-To Junkan”, 1989, 37 669-674.
Horn, F., et al., “J. Invest Dermatol”, 1987, 88, 220-222.
Raynaud, F. and Evain-Brion, D., “Br. J. Dermatol.”, 1991, 124, 542-546.
Hegemann, L., et al., “Arch. Dermatol. Res.”, 1991, 283, 456-460.
Bollag, W.B. et al., “J. Invest. Dermatol.”, 1993, 100, 240-246.
Karasik, A., et al., “J. Biol. Chem.”, 1990, 265, 10226-10231.
Chen, K.S., et al., “Trans. Assoc. Am. Physicians.”, 1991, 104, 206-212.
Chin, J.E., et al., “J. Biol. Chem.”, 1993, 268, 6338-6347.
Lee, T-S., et al., “J. Clin. Invest.”, 1989, 83, 90-94.
Lee, T-S., et al., “Proc. Natl. Acad. Sci. USA”, 1989, 86, 5141-5145.
Craven, PA. and DeRubertis, F.R., “J. Clin. Invest.”, 1989, 87, 1667-1675.
Tesfamariam, B., et al., “J. Clin. Invest.”, 1991, 87, 1643-1648.
G. Xie, et al., “Tetrahedron Lett.”, 1994, 35, 5555.
Wolf, B.A., et al., J. Clin. Invest., 1991, 87, 31-35.

Affiliated with

Also associated with

Rating

Indazolyl-substituted pyrroline compounds as kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Indazolyl-substituted pyrroline compounds as kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indazolyl-substituted pyrroline compounds as kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3475996